News
2022.05.26
New Location
More
2022.01.28
ImmuniT Research Inc. has entered into a non-exclusive license agreement with Boehringer Ingelheim of Germany for novel biomarkers for the treatment of cancer.
More
2021.12.08
Notice regarding US patent grant for our core technology “immunological biomarkers predicting clinical efficacy of cancer immunotherapy”
More
2021.10.01
Released “rippleT”, the immune profiling and monitoring system.
More
2021.09.27
The examining division of European Patent Office intends to grant an European patent to the invention entitled “Immunological biomarker for predicting clinical effect of cancer immunotherapy”, which is related to our core technology.
More
2020.07.15
ImmuniT Research Inc. has concluded the collaborative development and license agreement with Boehringer Ingelheim, Germany
More
2020.02.10
The paper by Dr. Hiroshi Kagamu, Scientific Advisor of ImmuniT Research Inc. as well as Professor at Department of Respiratory Medicine, Saitama Medical University International Medical Center, was on-line published in “Cancer Immunology Research”.
More
2020.02.04
The examiner’s assessment in Japan has been issued to the patent application for “Immunological biomarker for predicting clinical effect of cancer immunotherapy” filed by Saitama Medical University.
More
2020.01.16
New Location
More